OSR Health (OSRH) EBITDA (2022 - 2026)

OSR Health has disclosed EBITDA across 5 years of filings, most recently posting -$3.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 42.0% year-over-year to -$3.0 million; the TTM figure through Jun 2026 stood at -$16.9 million (down 26.76% YoY), while the FY2025 annual figure was -$18.3 million, down 56.86% from the prior year.
• EBITDA came in at -$3.0 million for Q2 2026 at OSR Health, up from -$3.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $530029.0 in Q2 2023 to a low of -$6.4 million in Q4 2025.
• Average EBITDA over 5 years is -$2.1 million, with a median of -$2.9 million recorded in 2025.
• Year-over-year, EBITDA jumped 53746.66% in 2023 and sank 2512.24% in 2024.
• Over 5 years, EBITDA stood at -$14252.0 in 2022, then soared by 569.18% to $66868.0 in 2023, then slumped by 2512.24% to -$1.6 million in 2024, then sank by 296.12% to -$6.4 million in 2025, then jumped by 52.53% to -$3.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$3.0 million in Q2 2026, -$3.7 million in Q1 2026, and -$6.4 million in Q4 2025.